STOCK TITAN

Exact Sciences Corporation - $EXAS STOCK NEWS

Welcome to our dedicated page for Exact Sciences Corporation news (Ticker: $EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exact Sciences Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exact Sciences Corporation's position in the market.

Rhea-AI Summary
Exact Sciences Corp. reports record revenue of $628 million in the third quarter of 2023, delivering over 1 million test results. Full-year revenue and adjusted EBITDA guidance raised by $28 million and $25 million, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
-
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) announced that company management will participate in several upcoming conferences and invited investors to participate by webcast. The conferences include Stifel Healthcare Conference, Jefferies London Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and Evercore ISI HealthCONx Conference. The webcasts can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
-
Rhea-AI Summary
Exact Sciences Corp. announces late-breaking data from the BLUE-C trial showing the next-generation Cologuard test met all study endpoints, demonstrating 94% sensitivity for colorectal cancer at 91% specificity. Results show next-generation Cologuard test superior to FIT in sensitivity for colorectal cancer and pre-cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Exact Sciences Corp. to present new data on early cancer detection and genomic testing at ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. to release Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
-
Rhea-AI Summary
Exact Sciences Corp. to present late-breaking data on next-generation Cologuard at the ACG Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
conferences
Rhea-AI Summary
Exact Sciences acquires Resolution Bioscience to enhance cancer treatment solutions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. to participate in Baird Global Healthcare Conference on September 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
conferences
-
Rhea-AI Summary
Exact Sciences Corp. selected for ComboMATCH clinical trials to analyze tumor samples using OncoExTra test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
Rhea-AI Summary
New research reveals barriers to colorectal cancer screening among 45-year-olds in the US
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
Exact Sciences Corporation

Nasdaq:EXAS

EXAS Rankings

EXAS Stock Data

9.84B
179.56M
1.01%
89.38%
3.49%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States of America
MADISON

About EXAS

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com